Novel In Vivo CD19 CAR-T Therapy Achieves Complete Remission in Aggressive DLBCL Without Lymphodepletion
• A heavily pretreated patient with relapsed/refractory diffuse large B-cell lymphoma achieved complete remission within 28 days following a single dose of Genocury Biotech's novel in vivo CD19 CAR-T therapy.
• The groundbreaking treatment eliminated the need for lymphodepletion—a standard yet toxic preconditioning step in traditional CAR-T protocols—while demonstrating complete absence of cytokine release syndrome and neurotoxicity.
• Genocury's proprietary technology delivers CAR payload directly into circulating T cells in vivo, potentially democratizing access to CAR-T therapy globally by reducing the $400,000 cost and 3-4 week timeline of traditional approaches.
Gene-Edited Pig Kidney Functions in Macaque for Over Six Months in Chinese Study
• Chinese scientists achieved a breakthrough by maintaining a gene-edited pig kidney's function in a macaque for 184 days, marking progress in xenotransplantation.
• The pig kidney, modified with four gene edits, functioned normally for five months in the macaque before chronic rejection began.
• Researchers used an improved immunosuppressive regimen to extend graft survival, aiming to pave the way for human clinical trials.
• This milestone brings China closer to international standards in xenotransplantation research, addressing the critical need for organ donors.
Equecabtagene Autoleucel Shows High Efficacy in Relapsed/Refractory Multiple Myeloma
• Equecabtagene Autoleucel demonstrated a 96% overall response rate in patients with relapsed/refractory multiple myeloma (R/RMM) who had received at least three prior therapies.
• The stringent complete response/complete response rate was 74.3%, with 95% of patients achieving minimal residual disease (MRD) negativity.
• The fully human anti-BCMA CAR-T therapy showed a favorable safety profile, with most cytokine release syndrome (CRS) cases being grade 1 or 2.
• A 12-month progression-free survival rate of 78.8% was observed, and 50% of patients had detectable vector copy number (VCN) at 12 months post-infusion.
Sintilimab Plus Bevacizumab Shows Promise in Relapsed Ovarian Clear Cell Carcinoma
• A phase II trial (INOVA) found that sintilimab combined with bevacizumab demonstrated activity in patients with relapsed or persistent ovarian clear cell carcinoma.
• The combination therapy achieved an objective response rate of 40.5% and a disease control rate of 73% in evaluable patients.
• Median progression-free survival was 6.9 months, and median overall survival reached 28.2 months with the sintilimab and bevacizumab regimen.
• The treatment showed a manageable safety profile, with mostly grade 3 treatment-related adverse events and no grade 4 or 5 events reported.
Optimal Lymphodepletion Improves Outcomes with Equecabtagene Autoleucel in Multiple Myeloma
• A post-hoc analysis of the FUMANBA-1 study reveals that standard lymphodepletion prior to Equecabtagene Autoleucel infusion enhances remission depth and duration in R/R MM patients.
• The standard-dose lymphodepletion group showed a significantly higher 12-month MRD negativity rate (90.4%) compared to the dose-adjusted group (63.7%), with HR=3.33 (P=0.0166).
• Progression-free survival at 12 months was also superior in the standard-dose group (92.2%) versus the dose-adjusted group (73.5%), with HR=3.64 (P=0.0032).
• No significant differences in the incidence or severity of CRS and ICANS were observed between the standard and dose-adjusted lymphodepletion groups.
© Copyright 2025. All Rights Reserved by MedPath